3rd Viral Vector Process Development & Manufacturing Summit

In recent industry news, AAV gene therapies are gaining momentum, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy market, valued at $1.5 billion in 2023, is projected to skyrocket to $22.3 billion by 2029. However, scaling up production remains a significant challenge, highlighting the urgency for innovative solutions in viral vector manufacturing.​

The 3rd Viral Vector Process Development & Manufacturing Summit returns to Boston to tackle these challenges head-on. Featuring over 16 expert speakers, including Yuanli Song, Associate Director at Sanofi, the event offers cutting-edge insights into process optimization for viral vector production. Yuanli Song emphasized the importance of this summit, saying, “This summit is a vital platform that brings together experts from diverse fields to address and solve pressing challenges in viral vector process development and manufacturing. The 2025 meeting will witness valuable discussions that will help drive innovation and advance solutions for optimizing viral vector production.”

The agenda includes two interactive workshops and over 20 hours of insightful content designed to address upstream and downstream challenges, improve yield, and enhance scalability. Additionally, attendees will benefit from 6+ hours of dedicated networking breaks, fostering collaborations crucial for advancing this field.

Key topics covered include:

• Enhancing capsid ratios and vector optimization
• Innovations in purification techniques
• Seamless tech transfer for scalability
• Tackling high-dose production complexities

This summit is the ultimate opportunity for professionals from companies like Sanofi, Kite, Ultragenyx, and others to stay at the forefront of viral vector manufacturing innovations. With 800+ gene therapy candidates in trials and the FDA’s evolving frameworks, this event is essential for driving the next wave of scalable, high–quality therapies​.

View our agenda to find out more!